Literature DB >> 22156707

White matter abnormalities in primary Sjögren syndrome.

M Akasbi1, J Berenguer, A Saiz, P Brito-Zerón, M Pérez-De-Lis, A Bové, C Diaz-Lagares, S Retamozo, Y Blanco, R Perez-Alvarez, X Bosch, A Sisó, F Graus, M Ramos-Casals.   

Abstract

OBJECTIVE: To describe the main characteristics of patients with primary Sjögren syndrome (SS) and white matter abnormalities (WMA) seen by a specialist SS unit.
METHODS: The study cohort included 321 consecutive patients fulfilling the 2002 classification criteria for primary SS. We retrospectively analyzed the results of neuroimaging studies performed in patients who presented with neurological symptoms. Patients were further evaluated by three neurologists to determine fulfillment of the McDonald criteria for the diagnosis of multiple sclerosis (MS).
RESULTS: Fifty-one (16%) patients had at least one neuroimaging study, and 25 of these had WMA. WMA were classified as vascular pathological changes in 21 patients: 10 had multiple small focal lesions, 7 had beginning confluence of lesions and 4 had diffuse involvement of the entire region. WMA were classified as inflammatory/demyelinating lesions (MS-like) in 4 patients who fulfilled the MRI Barkhof criteria. Patients with inflammatory/demyelinating lesions were younger (53.7 vs. 73.5 years, P = 0.001) and had a lower frequency of hypertension (25% vs. 86%, P = 0.031) and altered glomerular filtration rate (0% vs. 70%, P = 0.047) in comparison with patients with vascular lesions. The multivariate age-sex adjusted model including the seven variables which were statistically significant in the univariate analysis (antimalarial therapy, leukopenia, anti-La/SSB antibodies, diabetes, hypertension, metabolic syndrome and HDL-c levels) identified hypertension (P = 0.019) and HDL-c levels (P = 0.032) as independent predictors of WMA in primary SS patients.
CONCLUSION: Neuroimaging studies disclosed WMA in 49% of patients with primary SS and suspected neurological involvement. WMA were identified as vascular pathological changes in 80% of the patients, and hypertension and HDL-c levels as predictive factors for this association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156707     DOI: 10.1093/qjmed/hcr218

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  9 in total

Review 1.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Altered white matter structural connectivity in primary Sjögren's syndrome: a link-based analysis.

Authors:  Xiao-Dong Zhang; Jing-Li Li; Jia-Min Zhou; Zi-Ning Lu; Lin-Ru Zhao; Wen Shen; Jun-Hai Xu; Yue Cheng
Journal:  Neuroradiology       Date:  2022-05-19       Impact factor: 2.995

3.  Neurological Complications of Sjögren's Syndrome: Diagnosis and Management.

Authors:  Sara S McCoy; Alan N Baer
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-10-24

4.  Hospitalization Risks for Neurological Disorders in Primary Sjögren's Syndrome Patients.

Authors:  Radjiv Goulabchand; Audrey Gabelle; Xavier Ayrignac; Nicolas Malafaye; Pierre Labauge; Danièle Noël; Jacques Morel; Camille Roubille; Lucie Barateau; Philippe Guilpain; Thibault Mura
Journal:  J Clin Med       Date:  2022-04-01       Impact factor: 4.241

Review 5.  New insights into the impact of neuro-inflammation in rheumatoid arthritis.

Authors:  Nicholas R Fuggle; Franklyn A Howe; Rachel L Allen; Nidhi Sofat
Journal:  Front Neurosci       Date:  2014-11-06       Impact factor: 4.677

6.  A Little-Known Brain Imaging Feature in Neuromyelitis Optica Spectrum Disorder: A Leukodystrophy-Like Pattern.

Authors:  Jun Seok Lee; Moon Kyung Choi; Jae Joon Lee; Hung Youl Seok
Journal:  J Clin Neurol       Date:  2019-03-11       Impact factor: 3.077

7.  Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity.

Authors:  Dimitris K Karathanasis; Anna Rapti; Adrianos Nezos; Charalampos Skarlis; Constantinos Kilidireas; Clio P Mavragani; Maria Eleftheria Evangelopoulos
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

8.  Magnetic resonance brain imaging in patients with visual vertigo.

Authors:  Lea Pollak; Michael Osherov; Nadav Berkovitz; Inessa Beckerman; Rafael Stryjer; Sigal Tal
Journal:  Brain Behav       Date:  2015-10-14       Impact factor: 2.708

Review 9.  The role of inflammation in the development of epilepsy.

Authors:  Amna Rana; Alberto E Musto
Journal:  J Neuroinflammation       Date:  2018-05-15       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.